In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis

被引:221
作者
Petersen, PJ [1 ]
Labthavikul, P [1 ]
Jones, CH [1 ]
Bradford, PA [1 ]
机构
[1] Wyeth Ayerst Res, Infect Dis Discovery Res, Pearl River, NY 10965 USA
关键词
antibiotics; synergy; antagonism; susceptibility;
D O I
10.1093/jac/dki477
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study was undertaken to determine the interaction of tigecycline with 13 select antimicrobial agents against a wide variety of Gram-negative and Gram-positive bacterial isolates. Methods: Antibiotic interactions were assayed using the chequerboard MIC format and selected synergistic combinations were confirmed using time-kill kinetic analysis. Results: Microdilution chequerboard analysis of tigecycline in combination with amikacin, ampicillin/sulbactam, azithromycin, ciprofloxacin, colistin, imipenem, levofloxacin, piperacillin, piperacillin/tazobactam, polymyxin B, rifampicin, minocycline and vancomycin resulted in an interpretation of either no interaction or synergy. Time-kill kinetic analysis resulted in an interpretation of no interaction for all but one of the drug combinations that resulted in an interpretation of synergy by the chequerboard analysis. Antagonism was not observed for any combination when assayed by either method. Conclusions: The lack of antagonism seen with tigecycline combinations in both chequerboard and time-kill kinetic studies is an encouraging outcome, suggesting that tigecycline may prove to be effective in combination therapy as well as in monotherapy.
引用
收藏
页码:573 / 576
页数:4
相关论文
共 10 条
[1]   In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin [J].
Alou, L ;
Cafini, F ;
Sevillano, D ;
Unzueta, I ;
Prieto, J .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (05) :513-516
[2]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]   In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections [J].
Bradford, PA ;
Weaver-Sands, DT ;
Petersen, PJ .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S315-S332
[4]   Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa [J].
Cappelletty, DM ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :677-683
[5]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
[6]   In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus [J].
Jacqueline, C ;
Navas, D ;
Batard, E ;
Miegeville, AF ;
Le Mabecque, V ;
Kergueris, MF ;
Bugnon, D ;
Potel, G ;
Caillon, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :45-51
[7]   In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens [J].
Petersen, PJ ;
Bradford, PA ;
Weiss, WJ ;
Murphy, TM ;
Sum, PE ;
Projan, SJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2595-2601
[8]   REPRODUCIBILITY OF THE MICRODILUTION CHECKERBOARD METHOD FOR ANTIBIOTIC SYNERGY [J].
RAND, KH ;
HOUCK, HJ ;
BROWN, P ;
BENNETT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :613-615
[9]   Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician [J].
Rybak, MJ ;
McGrath, BJ .
DRUGS, 1996, 52 (03) :390-405
[10]   Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test [J].
White, RL ;
Burgess, DS ;
Manduru, M ;
Bosso, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1914-1918